Dependence of Castration-Resistant Prostate Cancer (CRPC) Stem Cells on CRPC-Associated Fibroblasts

被引:22
|
作者
Adisetiyo, Helty [1 ,2 ]
Liang, Mengmeng [3 ]
Liao, Chun-Peng [4 ]
Jeong, Joseph H. [5 ]
Cohen, Michael B. [6 ]
Roy-Burman, Pradip [1 ,3 ]
Frenkel, Baruch [1 ,2 ,7 ]
机构
[1] Univ So Calif, Los Angeles, CA 90033 USA
[2] Univ So Calif, Inst Med Genet, Los Angeles, CA 90033 USA
[3] Univ So Calif, Dept Pathol, Los Angeles, CA 90033 USA
[4] Univ So Calif, Keck Sch Med, Ctr Appl Mol Med, Los Angeles, CA 90033 USA
[5] Med Coll Wisconsin, Dept Dermatol, Milwaukee, WI 53226 USA
[6] Univ Utah, Dept Pathol, Salt Lake City, UT USA
[7] Univ So Calif, Dept Orthopaed Surg, Los Angeles, CA 90033 USA
基金
美国国家卫生研究院;
关键词
RB DEFICIENCY; IN-VITRO; TUMORIGENESIS; THERAPY; MODELS; NICHE; P53;
D O I
10.1002/jcp.24546
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
We previously established a role for cancer-associated fibroblasts (CAF) in enhancing the self-renewal and differentiation potentials of putative prostate cancer stem cells (CSC). Our published work focused on androgen-dependent prostate cancer (ADPC) using the conditional Pten deletion mouse model. Employing the same model, we now describe the interaction of CAF and CSC in castration-resistant prostate cancer (CRPC). CAF isolated from ADPC (ADPCAF) and from CRPC (CRPCAF) were compared in terms of their ability to support organoid formation and tumor initiation by CSC from CRPC (CRPCSC) in vitro and in vivo. CRPCSC formed spheroids in vitro and well-differentiated glandular structures under the renal capsules of recipient mice in vivo more effectively in the presence of CRPCAF compared to ADPCAF. Furthermore, whereas CSC with CAF from ADPC formed mostly well-differentiated tumors in our previous study, we now show that CRPCSC, when combined with CRPCAF (but not ADPCAF), can form aggressive, poorly-differentiated tumors. The potential of CRPCAF to support organoid/tumor formation by CRPCSC remained greater even when compared to 10-fold more ADPCAF, suggesting that paracrine factors produced specifically by CRPCAF preferentially potentiate the stemness and tumorigenic properties of the corresponding CSC. This apparently unique property of CRPCAF was notable when the CAF and CSC were grafted in either intact or castrated recipient mice. In both environments, CRPCAF induced in the epithelial compartment higher proliferative activity compared to ADPCAF, indicated by a higher Ki67 index. Factors released by CRPCAF to regulate CRPCSC may be targeted to develop novel therapeutic approaches to manage advanced prostate cancer. J. Cell. Physiol. 229: 1170-1176, 2014. (c) 2014 Wiley Periodicals, Inc.
引用
收藏
页码:1170 / 1176
页数:7
相关论文
共 50 条
  • [1] Castration-resistant prostate cancer (CRPC)
    Loidl, W.
    Luger, F.
    Roosen, A.
    UROLOGE, 2014, 53 (03): : 391 - 399
  • [2] Castration-resistant prostate cancer (CRPC) [Kastrationsrefraktäres prostatakarzinom (CRPC)]
    Loidl W.
    Luger F.
    Roosen A.
    Der Urologe, 2014, 53 (3): : 391 - 401
  • [3] Mechanisms of resistance in castration-resistant prostate cancer (CRPC)
    Chandrasekar, Thenappan
    Yang, Joy C.
    Gao, Allen C.
    Evans, Christopher P.
    TRANSLATIONAL ANDROLOGY AND UROLOGY, 2015, 4 (03) : 365 - 380
  • [4] Role of Immunotherapy in Castration-Resistant Prostate Cancer (CRPC)
    Suarez, Cristina
    Morales-Barrera, Rafael
    Ramos, Victor
    Nunez, Isaac
    Valverde, Claudia
    Planas, Jacques
    Morote, Juan
    Maldonado, Xavier
    Carles, Joan
    BJU INTERNATIONAL, 2014, 113 (03) : 367 - 375
  • [5] CASTRATION-RESISTANT PROSTATE CANCER (CRPC): A UK EPIDEMIOLOGY STUDY
    Morgan, C.
    McEwan, P.
    Chamberlain, G.
    Cabrera, C.
    Parry, D.
    VALUE IN HEALTH, 2010, 13 (03) : A26 - A26
  • [6] DISEASE BURDEN OF CASTRATION-RESISTANT PROSTATE CANCER (CRPC) IN CHINA
    Ma, F. F.
    Liu, Q.
    Wang, J.
    Zhang, X. J.
    Yu, F.
    VALUE IN HEALTH, 2020, 23 : S451 - S452
  • [7] Novel therapeutics for the management of castration-resistant prostate cancer (CRPC)
    Lee, Daniel J.
    Cha, Eugene K.
    Dubin, Justin M.
    Beltran, Himisha
    Chromecki, Thomas F.
    Fajkovic, Harun
    Scherr, Douglas S.
    Tagawa, Scott T.
    Shariat, Shahrokh F.
    BJU INTERNATIONAL, 2012, 109 (07) : 968 - +
  • [8] Retreatment with docetaxel in metastatic castration-resistant prostate cancer (CRPC).
    Gernone, A.
    Pagliarulo, A.
    Pagliarulo, V.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [9] Second line therapy for castration-resistant prostate cancer (CRPC)
    Molitor, B.
    Boergermann, C.
    UROLOGE, 2012, 51 (03): : 357 - 362
  • [10] Zweitlinientherapie beim kastrationsresistenten Prostatakarzinom (CRPC)Second line therapy for castration-resistant prostate cancer (CRPC)
    B. Molitor
    C. Börgermann
    Der Urologe, 2012, 51 (3): : 357 - 362